Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW, PMDA Set Up “Preparatory Offices” to Plan Future Support System for Startups
October 5, 2016
-
REGULATORY Bayer Launches Recall of Hemophilia Med Kogenate over Potency Loss
October 4, 2016
-
BUSINESS Mitsubishi Tanabe Looks to Double Late-Stage Pipelines; Faster Decisions Hold Key in Curbing Costs
October 3, 2016
-
REGULATORY MHLW Says It Will Compile “Optimal Use Guidelines” for Keytruda Too
October 3, 2016
-
BUSINESS Suzuken’s Harvoni Sales Sag 70% from Peak, Wholesaler Earnings Certain to Take Hit
September 30, 2016
-
REGULATORY Drug Costs Biggest Driver of Healthcare Spending Surge: Chuikyo JMA Rep
September 29, 2016
-
BUSINESS Tokyo Startup’s Osteoarthritis Drug Hopeful on Tap for PIb Launch by Year-End
September 28, 2016
-
REGULATORY Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
September 27, 2016
-
TRENDS Japan’s Established Drug Market Shines as Renewed Opportunity for Foreign Generic Firms
September 26, 2016
-
REGULATORY Pharma, Govt Hold 1st Kanmin Taiwa Working Group Talks; Industry Calls for Trial-Friendly Environment, Discussions on Pricing
September 23, 2016
-
BUSINESS Nichi-Iko to Set up Biosimilar Dept. in October to Push Remicade Follow-On
September 21, 2016
-
BUSINESS Eisai Looks to Achieve CAGR of 55% for Fycompa with Add’l Indications
September 20, 2016
-
REGULATORY As Personal Info Law Amendment Looms, Govt Official Tells Drug Makers to Review Info in Hand
September 16, 2016
-
REGULATORY Industry Chiefs, Chuikyo Panelists Trade Barbs over Market Expansion on Add’l Indications
September 15, 2016
-
BUSINESS Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache
September 14, 2016
-
REGULATORY Blue Book “Will Be Used as Reference When Selecting Generics”: Panel Chair
September 14, 2016
-
REGULATORY G7 Health Ministers Adopt Kobe Communique
September 13, 2016
-
REGULATORY Generics from 5 Companies Enough When Major Products Lose Patent Protection: Top Bureaucrat
September 13, 2016
-
BUSINESS Nippon Shinyaku on Track to Achieve Targets in Midterm Plan with Sales of Selexipag Above Expectations: President
September 12, 2016
-
REGULATORY MHLW Panel Backs BI’s Triple Combo After 3rd Try
September 9, 2016
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…